Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Tumor Necrosis Factor Inhibitors Market Research Report 2019-2025

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Tumor Necrosis Factor Inhibitors Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Tumor Necrosis Factor Inhibitors Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Type
    • 1.4.2 Humira
    • 1.4.3 Enbrel
    • 1.4.4 Remicade
    • 1.4.5 Others
  • 1.5 Market by Application
    • 1.5.1 Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Application
    • 1.5.2 Alzheimer's Diseases
    • 1.5.3 Parkinson's Diseases
    • 1.5.4 Ischemic Stroke
    • 1.5.5 Multiple Sclerosis
    • 1.5.6 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Tumor Necrosis Factor Inhibitors Market Size, Estimates and Forecasts
    • 2.1.1 Global Tumor Necrosis Factor Inhibitors Revenue 2015-2026
    • 2.1.2 Global Tumor Necrosis Factor Inhibitors Sales 2015-2026
  • 2.2 Global Tumor Necrosis Factor Inhibitors, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Tumor Necrosis Factor Inhibitors Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Tumor Necrosis Factor Inhibitors Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Tumor Necrosis Factor Inhibitors Competitor Landscape by Players

  • 3.1 Tumor Necrosis Factor Inhibitors Sales by Manufacturers
    • 3.1.1 Tumor Necrosis Factor Inhibitors Sales by Manufacturers (2015-2020)
    • 3.1.2 Tumor Necrosis Factor Inhibitors Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Tumor Necrosis Factor Inhibitors Revenue by Manufacturers
    • 3.2.1 Tumor Necrosis Factor Inhibitors Revenue by Manufacturers (2015-2020)
    • 3.2.2 Tumor Necrosis Factor Inhibitors Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Tumor Necrosis Factor Inhibitors Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Inhibitors Revenue in 2019
    • 3.2.5 Global Tumor Necrosis Factor Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Tumor Necrosis Factor Inhibitors Price by Manufacturers
  • 3.4 Tumor Necrosis Factor Inhibitors Manufacturing Base Distribution, Product Types
    • 3.4.1 Tumor Necrosis Factor Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Tumor Necrosis Factor Inhibitors Product Type
    • 3.4.3 Date of International Manufacturers Enter into Tumor Necrosis Factor Inhibitors Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Tumor Necrosis Factor Inhibitors Market Size by Type (2015-2020)
    • 4.1.1 Global Tumor Necrosis Factor Inhibitors Sales by Type (2015-2020)
    • 4.1.2 Global Tumor Necrosis Factor Inhibitors Revenue by Type (2015-2020)
    • 4.1.3 Tumor Necrosis Factor Inhibitors Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Tumor Necrosis Factor Inhibitors Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Tumor Necrosis Factor Inhibitors Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Type (2021-2026)
    • 4.2.3 Tumor Necrosis Factor Inhibitors Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Tumor Necrosis Factor Inhibitors Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Tumor Necrosis Factor Inhibitors Market Size by Application (2015-2020)
    • 5.1.1 Global Tumor Necrosis Factor Inhibitors Sales by Application (2015-2020)
    • 5.1.2 Global Tumor Necrosis Factor Inhibitors Revenue by Application (2015-2020)
    • 5.1.3 Tumor Necrosis Factor Inhibitors Price by Application (2015-2020)
  • 5.2 Tumor Necrosis Factor Inhibitors Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Tumor Necrosis Factor Inhibitors Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Tumor Necrosis Factor Inhibitors Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Tumor Necrosis Factor Inhibitors by Country
    • 6.1.1 North America Tumor Necrosis Factor Inhibitors Sales by Country
    • 6.1.2 North America Tumor Necrosis Factor Inhibitors Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
  • 6.3 North America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Tumor Necrosis Factor Inhibitors by Country
    • 7.1.1 Europe Tumor Necrosis Factor Inhibitors Sales by Country
    • 7.1.2 Europe Tumor Necrosis Factor Inhibitors Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
  • 7.3 Europe Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Tumor Necrosis Factor Inhibitors by Region
    • 8.1.1 Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Region
    • 8.1.2 Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
  • 8.3 Asia Pacific Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Tumor Necrosis Factor Inhibitors by Country
    • 9.1.1 Latin America Tumor Necrosis Factor Inhibitors Sales by Country
    • 9.1.2 Latin America Tumor Necrosis Factor Inhibitors Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
  • 9.3 Central & South America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Tumor Necrosis Factor Inhibitors by Country
    • 10.1.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country
    • 10.1.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
  • 10.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

11 Company Profiles

  • 11.1 EPIRUS Biopharmaceuticals
    • 11.1.1 EPIRUS Biopharmaceuticals Corporation Information
    • 11.1.2 EPIRUS Biopharmaceuticals Description and Business Overview
    • 11.1.3 EPIRUS Biopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
    • 11.1.5 EPIRUS Biopharmaceuticals Related Developments
  • 11.2 Bionovis
    • 11.2.1 Bionovis Corporation Information
    • 11.2.2 Bionovis Description and Business Overview
    • 11.2.3 Bionovis Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Bionovis Tumor Necrosis Factor Inhibitors Products Offered
    • 11.2.5 Bionovis Related Developments
  • 11.3 CASI Pharmaceuticals
    • 11.3.1 CASI Pharmaceuticals Corporation Information
    • 11.3.2 CASI Pharmaceuticals Description and Business Overview
    • 11.3.3 CASI Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
    • 11.3.5 CASI Pharmaceuticals Related Developments
  • 11.4 Janssen Biotech
    • 11.4.1 Janssen Biotech Corporation Information
    • 11.4.2 Janssen Biotech Description and Business Overview
    • 11.4.3 Janssen Biotech Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Products Offered
    • 11.4.5 Janssen Biotech Related Developments
  • 11.5 Momenta Pharmaceuticals
    • 11.5.1 Momenta Pharmaceuticals Corporation Information
    • 11.5.2 Momenta Pharmaceuticals Description and Business Overview
    • 11.5.3 Momenta Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
    • 11.5.5 Momenta Pharmaceuticals Related Developments
  • 11.6 GlaxoSmithKline
    • 11.6.1 GlaxoSmithKline Corporation Information
    • 11.6.2 GlaxoSmithKline Description and Business Overview
    • 11.6.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Products Offered
    • 11.6.5 GlaxoSmithKline Related Developments
  • 11.7 HanAll Biopharma
    • 11.7.1 HanAll Biopharma Corporation Information
    • 11.7.2 HanAll Biopharma Description and Business Overview
    • 11.7.3 HanAll Biopharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Products Offered
    • 11.7.5 HanAll Biopharma Related Developments
  • 11.8 Intas Pharmaceuticals
    • 11.8.1 Intas Pharmaceuticals Corporation Information
    • 11.8.2 Intas Pharmaceuticals Description and Business Overview
    • 11.8.3 Intas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
    • 11.8.5 Intas Pharmaceuticals Related Developments
  • 11.9 LEO Pharma
    • 11.9.1 LEO Pharma Corporation Information
    • 11.9.2 LEO Pharma Description and Business Overview
    • 11.9.3 LEO Pharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 LEO Pharma Tumor Necrosis Factor Inhibitors Products Offered
    • 11.9.5 LEO Pharma Related Developments
  • 11.10 Dexa Medica
    • 11.10.1 Dexa Medica Corporation Information
    • 11.10.2 Dexa Medica Description and Business Overview
    • 11.10.3 Dexa Medica Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Dexa Medica Tumor Necrosis Factor Inhibitors Products Offered
    • 11.10.5 Dexa Medica Related Developments
  • 11.1 EPIRUS Biopharmaceuticals
    • 11.1.1 EPIRUS Biopharmaceuticals Corporation Information
    • 11.1.2 EPIRUS Biopharmaceuticals Description and Business Overview
    • 11.1.3 EPIRUS Biopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
    • 11.1.5 EPIRUS Biopharmaceuticals Related Developments
  • 11.12 MedImmune
    • 11.12.1 MedImmune Corporation Information
    • 11.12.2 MedImmune Description and Business Overview
    • 11.12.3 MedImmune Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 MedImmune Products Offered
    • 11.12.5 MedImmune Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Tumor Necrosis Factor Inhibitors Market Estimates and Projections by Region
    • 12.1.1 Global Tumor Necrosis Factor Inhibitors Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Regions 2021-2026
  • 12.2 North America Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
    • 12.2.1 North America: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
    • 12.2.2 North America: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
    • 12.2.3 North America: Tumor Necrosis Factor Inhibitors Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
    • 12.3.2 Europe: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Tumor Necrosis Factor Inhibitors Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Tumor Necrosis Factor Inhibitors Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Tumor Necrosis Factor Inhibitors Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Tumor Necrosis Factor Inhibitors Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Tumor Necrosis Factor Inhibitors Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Tumor Necrosis Factor Inhibitors Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Tumor Necrosis Factor Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Tumor Necrosis Factor Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Tumor Necrosis Factor Inhibitors market is segmented into
    Humira
    Enbrel
    Remicade
    Others

    Segment by Application, the Tumor Necrosis Factor Inhibitors market is segmented into
    Alzheimer's Diseases
    Parkinson's Diseases
    Ischemic Stroke
    Multiple Sclerosis
    Others

    Regional and Country-level Analysis
    The Tumor Necrosis Factor Inhibitors market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Tumor Necrosis Factor Inhibitors market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Tumor Necrosis Factor Inhibitors Market Share Analysis
    Tumor Necrosis Factor Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Tumor Necrosis Factor Inhibitors business, the date to enter into the Tumor Necrosis Factor Inhibitors market, Tumor Necrosis Factor Inhibitors product introduction, recent developments, etc.

    The major vendors covered:
    EPIRUS Biopharmaceuticals
    Bionovis
    CASI Pharmaceuticals
    Janssen Biotech
    Momenta Pharmaceuticals
    GlaxoSmithKline
    HanAll Biopharma
    Intas Pharmaceuticals
    LEO Pharma
    Dexa Medica
    LG Life Sciences
    MedImmune

    Buy now